Sichuan Huiyu Pharmaceutical Co.,Ltd. (ASX: 688553) has announced that its subsidiaries, Seacross Pharmaceuticals Ltd. and Seacross (Europe) Pharma Ltd., have recently received marketing authorizations for several of the company's products from regulatory authorities in multiple countries.

The approvals, granted by the National Agency for Regulation of Medical and Pharmaceutical Activities of Georgia, the Austrian Agency for Health and Food Safety, the Spanish Agency of Medicines and Medical Devices, the Portuguese National Authority of Medicines and Health Products, the Dutch Medicines Evaluation Board, and the Saudi Food and Drug Authority, cover a range of injectable products.

The authorized products include Pemetrexed Disodium for Injection, Irinotecan Hydrochloride Injection, Oxaliplatin Injection, Paclitaxel Injection, Fulvestrant Injection, Paclitaxel for Injection (Albumin Bound), Decitabine for Injection, and Sodium Thiosulfate Injection.

Securing these approvals in Georgia, Austria, Spain, Portugal, the Netherlands, and Saudi Arabia is expected to enhance the company's international product portfolio. This development is seen as strengthening the company's brand image in global markets and broadening the scope and depth of its international operations, thereby laying a more solid foundation for sustainable growth in overseas markets.